Details

Autor(en) / Beteiligte

• Lapostolle, Frédéric
• van’t Hof, Arnoud W.
• Hamm, Christian W.
• Stibbe, Olivier
• Ecollan, Patrick
• Collet, Jean-Philippe
• Silvain, Johanne
• Lassen, Jens Flensted
• Heutz, Wim M. J. M.
• Bolognese, Leonardo
• Cantor, Warren J.
• Cequier, Angel
• Chettibi, Mohamed
• Goodman, Shaun G.
• Hammett, Christopher J.
• Huber, Kurt
• Janzon, Magnus
• Merkely, Béla
• Storey, Robert F.
• ten Berg, Jur
• Zeymer, Uwe
• Licour, Muriel
• Tsatsaris, Anne
• Montalescot, Gilles

Titel

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine

Ist Teil von

• American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019-04, Vol.19 (2), p.173-183

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2019

Quelle

Springer LINK 全文期刊数据库

Beschreibungen/Notizen

• Background Morphine adversely impacts the action of oral adenosine diphosphate (ADP)-receptor blockers in ST-segment elevation myocardial infarction (STEMI) patients, and is possibly associated with differing patient characteristics. This retrospective analysis investigated whether interaction between morphine use and pre-percutaneous coronary intervention (pre-PCI) ST-segment elevation resolution in STEMI patients in the ATLANTIC study was associated with differences in patient characteristics and management. Methods ATLANTIC was an international, multicenter, randomized study of treatment in the acute ambulance/hospital setting where STEMI patients received ticagrelor 180 mg ± morphine. Patient characteristics, cardiovascular history, risk factors, management, and outcomes were recorded. Results Opioids (97.6% morphine) were used in 921 out of 1862 patients (49.5%). There were no significant differences in age, sex or cardiovascular history, but more morphine-treated patients had anterior myocardial infarction and left-main disease. Time from chest pain to electrocardiogram and ticagrelor loading was shorter with morphine (both p  = 0.01) but not total ischemic time. Morphine-treated patients more frequently received glycoprotein IIb/IIIa inhibitors ( p  = 0.002), thromboaspiration and stent implantation (both p  < 0.001). No significant difference between the two groups was found regarding pre-PCI ≥ 70% ST-segment elevation resolution, death, myocardial infarction, stroke, urgent revascularization and definitive acute stent thrombosis. More morphine-treated patients had an absence of pre-PCI Thrombolysis in Myocardial Infarction (TIMI) 3 flow (85.8% vs. 79.7%; p  = 0.001) and more had TIMI major bleeding (1.1% vs. 0.1%; p  = 0.02). Conclusions Morphine-treatment was associated with increased GP IIb/IIIa inhibitor use, less pre-PCI TIMI 3 flow, and more bleeding. Judicious morphine use is advised with non-opioid analgesics preferred for non-severe acute pain. Trial Registration clinicaltrials.gov identifier: NCT01347580.